The 34 references in paper A. Essaian M., I. Zaripova V., А. Есаян М., И. Зарипова В. (2010) “ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ БЛОКАТОРОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II У ДИАЛИЗНЫХ ПАЦИЕНТОВ // EFFICACY AND SAFETY OF ANGIOTENSIN II RECEPTOR BLOCKERS IN DIALYSIS PATIENTS” / spz:neicon:nefr:y:2010:i:3:p:13-16

1
Шутов АМ, Куликова ЕС, Ивашкина ТН и др. Диасто­ лическая дисфункция и клинические проявления сердеч­ ной недостаточности у больных с додиализной хронической почечной недостаточностью. Нефрология 2001; 5 (4): 30-34
(check this in PDF content)
2
Folley RN, Parfrey PS, Sarnac MJ. Epidemiology of cardiovascular diseases in chronic renal failure. J Am Soc Nephrol 1998; 9 (10): 16-23
(check this in PDF content)
3
Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141 (2): 334­ 341
(check this in PDF content)
4
Agabiti-Rosei E, Muiesan ML, Salvetti M.. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy. J Am Soc Nephrol 2006; 17 (1): 104-108
(check this in PDF content)
5
U.S. Renal Data System: USRDS 2008 annual data report. The National Institutes of Health. 2008. Am J Kidney Dis 2009; 1(Suppl 1):S1
(check this in PDF content)
6
Томилина НА, Бикбов БТ. Эпидемиология хроничес­ кой почечной недостаточности и новые подходы к класси­ фикации и оценке тяжести хронических прогрессирующих заболеваний почек. Тер арх 2005; 77 (6): 87-92
(check this in PDF content)
7
Ringoir S. An update on uremic toxins. Kidney Int 1997; 52 (Suppl 62): 2-4
(check this in PDF content)
8
MаcMahon AC, Greenwald SE, Dodd SM et al. Prolonged calcium transient and myocardial remodeling in early experimental uremia. Nephr Dial Transplant 2002; 17 (5): 759­ 764
(check this in PDF content)
9
Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Current Opinion in Nephrology & Hypertension 2009; 18 (3): 181-188
(check this in PDF content)
10
Zocalli C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002; 17(11): 50-54
(check this in PDF content)
11
Волгина ГВ. Клиническая эпидемиология кардио­ васкулярных нарушений при ХПН (Обзор литературы). Не­ фрология и диализ 2000; 2 (1): 25-32
(check this in PDF content)
12
Goldsmith D, MacGinley R, Smith A, Covic A. How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure. Nephrol Dial Transplant 2002; 17 (6): 965-969
(check this in PDF content)
13
London GM, Marchais S, Guerin AP et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17 (10): 1713-1724
(check this in PDF content)
14
Schmieder R, Hilgers K, Schlaich M, Schmidt B. Renin- angiotensin system and cardiovascular risk. The Lancet 2007; 369 (9568): 1208 - 1219
(check this in PDF content)
15
Sica D. Angiotensin receptor blockers: new considerations in their mechanism of action. J Clin Hypertens (Greenwich) 2006; 8 (5): 381-385
(check this in PDF content)
16
Cuspidi C, Meani S, Valerio C et al. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. Blood Press 2006; 15(2): 107-15
(check this in PDF content)
17
Dahlof B, Zanchetti A, Diez J, Nicholls MG et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy (REGAAL Study Investigators). J Hypertens 2002; 20(9): 1855-1864
(check this in PDF content)
18
Cuspidi C, M. Muiesan L, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. Journal of Hypertension 2002; 20 (11): 2293-2300
(check this in PDF content)
19
Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009; 2009: 752406
(check this in PDF content)
20
Koh K, Ahn JY, Han SH et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients J Am Col Cardiol 2003; 42(5): 905-910
(check this in PDF content)
21
Suzuki H, Kanno Y, Sugahara S et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52(3): 400-402
(check this in PDF content)
22
Takahashi A, Takase H, Toriyama T et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. Nephrol Dial Transplant 2006; 21(9): 2507-2512
(check this in PDF content)
23
Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90(3): 256-261
(check this in PDF content)
24
Kanno X Kaneko K, Kaneko M et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43(3): 380-386
(check this in PDF content)
25
Tian Jun-Ping, Wang Tao, Wang Hong, The Prevalence of Left Ventricular Hypertrophy in Chinese Hemodialysis Patients Is Higher Than That in Peritoneal Dialysis Patients. Renal Failure 2008; 30(5): 391-400
(check this in PDF content)
26
Shigenaga A, Tamura K, Dejima T et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009; 112(1): 31-40
(check this in PDF content)
27
Suzuki H, Nakamoto H, Okada H et al. A Selective Angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis 2003; 19(1): 50-66
(check this in PDF content)
28
Wen-Hung Huang, Ching-Wei Hsu, Yung-Chang Chen. Angiotensin II Receptor Antagonists Supplementation is Associated with Arterial Stiffness: Insight from a Retrospective Study in 116 Peritoneal Dialysis Patients. Renal Failure 2007;
(check this in PDF content)
29
7): 843-848 29. Suzuki H, Kanno X Kaneko K. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004; 8(4): 320­ 327.
(check this in PDF content)
30
Fujii H, Nakahama H, Yoshihara F, et al. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. Kobe J Med Sci 2005; 51(1): 1-6
(check this in PDF content)
31
Карабаева АЖ. Альдостерон как фактор прогресси­ рования кардиоваскулярных осложнений при хронической болезни почек. Автореф. дис. д-ра. мед. наук. СПб., 2009
(check this in PDF content)
32
W Fang, Oreopoulos D, Bargman J. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrology Dial Transplant 2008; 23(11): 3704-3710
(check this in PDF content)
33
Sica D. Renal handling of angiotensin receptor blockers: Clinical relevance. Current Hypertension Reports 2003; 5(4): 337-339
(check this in PDF content)
34
Gradman A, Michelson E. Comparative effects of candesartan cllexetil and losartan in systemic hypertension. AJH-APRIL 1999; 12(4 part 2): 121A Поступила в редакцию 19.07.2010 г. Принята в печать 16.09.2010 г.
(check this in PDF content)